What is autoimmune hepatitis?

Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease in which host immune activity targets hepatocytes, producing necroinflammatory liver injury that can progress to fibrosis and cirrhosis. The diagnosis is not secured by a single test; it relies on integration of clinical presentation, pattern of liver injury, characteristic autoantibodies, immunoglobulin G (IgG) elevation, histology, exclusion of competing etiologies (especially viral hepatitis and drug-induced liver injury), and, in many patients, response to immunosuppression.

Because presentations vary from incidental enzyme abnormalities to acute icteric hepatitis or even acute liver failure, clinicians often need a structured framework when AIH is suspected. In research settings, the International Autoimmune Hepatitis Group (IAIHG) maintained a comprehensive revised scoring system with many weighted domains; while useful for complex or atypical cases, that system is labor-intensive for day-to-day practice.

Why a simplified score exists

The simplified AIH diagnostic score was developed to distill the essential decision information into a small number of domains with clear cutoffs, each graded in a simple way. The rationale is pragmatic: clinicians can apply it when biopsy and serology are available and when viral hepatitis and other common mimics have been addressed systematically. The score is best understood as a structured checklist with numeric weights, not a stand-alone biomarker.

Compared with older multi-parameter systems, the simplified instrument intentionally reduces cognitive load while retaining items that carry the largest discriminative value in typical cohort studies: circulating autoantibodies, IgG elevation relative to the laboratory reference interval, liver pathology aligned with AIH, and documentation that active viral hepatitis is not the primary explanation.

Structure of the simplified score

The simplified system uses four domains. Within each domain, the patient is classified into ordered categories that map to 0, 1, or 2 points. Points are summed across domains. In the developmental and validation analyses around the original proposed simplification, totals reaching at least 6 points supported a classification of probable AIH, whereas totals reaching at least 7 points aligned with definite AIH under the simplified framework.

Across all patients, the theoretical maximum is 8 points when every domain contributes its maximum. In real patients, combinations such as high-titer serology, marked IgG elevation, histology judged typical of AIH, and confirmed viral exclusion will cluster near the top of the range; conversely, normal IgG, absent or only borderline autoantibodies, histology not compatible with AIH, or unresolved viral disease drive scores toward the bottom.

Domain 1: Autoantibodies

AIH is strongly associated with characteristic autoantibody profiles. The simplified score continues to anchor diagnosis in the same immunologic signals emphasized in broader IAIHG consensus discussions: antinuclear antibody (ANA) and smooth muscle antibody (SMA) for type 1–predominant patterns, anti–liver kidney microsomal type 1 (anti-LKM1) in type 2 disease as defined historically, and recognition of anti–soluble liver antigen / liver-pancreas (anti-SLA/LP) as a high-specificity marker when present.

The score assigns:

• One point when ANA or SMA reach low-positive immunofluorescence thresholds used in the original description (commonly ≥1:40 for those patterns in adults when tested by indirect immunofluorescence on appropriate substrate).
• Two points when a higher autoantibody threshold is met: ANA or SMA ≥1:80, or anti-LKM1 ≥1:40, or positivity for anti-SLA in assays designed for that specificity.

A critical rule embedded in the simplified score is that autoantibody points are capped: even if multiple assays are abnormal, the domain should not exceed the maximum points for autoantibodies. In practice, clinicians select the single best-supported tier after reviewing the complete autoantibody panel, assay methodology, and whether low-positive ANA in isolation might reflect non-AIH conditions.

Assay interpretation caveat: Many laboratories screen ANA with solid-phase or bead-based platforms. Those results are not numerically interchangeable with classical immunofluorescence titers, and false-negative ANA by automated methods has been emphasized in rheumatology and hepatology discussions alike. When the numeric score depends on titer cutoffs, document how positivity was defined and, when feasible, align interpretations with immunofluorescence or follow institutional expert guidance.

Domain 2: IgG relative to the upper limit of normal

Elevation of polyclonal IgG is a biochemical hallmark that supports immune activation consistent with AIH, particularly when not fully explained by cirrhosis alone or alternative protein loss states. The simplified score uses the patient’s IgG in relation to the laboratory-specific upper limit of normal (ULN), which varies by assay, age, and reference population.

• One point is assigned when IgG is above the laboratory ULN but has not reached the higher multiplier threshold described in the simplified table.
• Two points are assigned when IgG exceeds 1.10 times the ULN—that is, roughly a 10% lift beyond the reference upper bound, a threshold intended to capture more pronounced humoral immune activation.

Clinicians should interpret IgG in clinical context. Mild hypergammaglobulinemia occurs in chronic inflammation from many causes; isolated mild elevation without supportive histology or autoantibodies lowers confidence in AIH. Conversely, biochemically “normal” IgG does not fully exclude AIH—especially early in disease, in treated patients, or in individuals with naturally low baseline immunoglobulin levels—so discordance between IgG and other domains should trigger expert review rather than premature closure.

Domain 3: Liver histology

Liver biopsy remains central to how guideline writers frame AIH diagnosis, not only for scoring systems but also for severity assessment and detection of overlapping pathology. The simplified score awards histology points based on how closely the specimen matches patterns considered compatible with or typical of AIH.

The prototypical lesion emphasized in teaching and in classical scoring discussions is interface hepatitis (also termed piecemeal necrosis): a dense portal and periportal infiltrate rich in lymphocytes and plasma cells that disrupts the limiting plate and extends into adjacent lobules. Additional features such as hepatocyte rosettes, pan-acinar inflammation in acute presentations, and bridging necrosis can appear depending on tempo, prior therapy, and sampling.

• One point reflects histology interpreted as compatible with AIH—helpful supportive inflammation and interface activity but without the full constellation or with sampling limitations.
• Two points reflect histology judged typical of AIH in the grading scheme used in the published simplified criteria—generally a stronger match to classic interface hepatitis with supportive plasma-cell richness and absence of features that principally suggest an alternative first diagnosis.

Biopsy interpretation must actively consider mimics and overlap. Prominent bile duct injury, florid duct lesions, or cholangiocentric patterns may point toward primary biliary cholangitis or primary sclerosing cholangitis overlap rather than “pure” AIH. Steatohepatitic, vascular, or drug-related patterns may reduce histologic compatibility even when autoantibodies are positive. Because needle biopsy samples only a small fraction of the organ, discordance between histology and serology should be approached with repeat sampling or multidisciplinary review when clinical stakes are high.

Domain 4: Exclusion of viral hepatitis

Chronic viral hepatitides, especially hepatitis B and C, can produce enzyme elevations, autoantibody low-titer positivity, and inflammatory histology that superficially resembles AIH. For that reason, the simplified score awards two points when absence of viral hepatitis is established by an appropriate negative evaluation for clinically relevant hepatotropic viruses in context—commonly including workup for hepatitis B surface antigen and hepatitis C antibody with reflex RNA testing when indicated, and expanded testing when acute viral syndromes or epidemiologic risks suggest hepatitis A or E.

This domain is explicitly about ruling in immune-mediated disease as the working construct after excluding infections that would change management. It should be applied alongside, not instead of, standard-of-care testing completeness: indeterminate serologies, recent exposures, or perinatal/immunosuppression-related HBV reactivation risk all require tailored algorithms that the score cannot encode.

Interpreting the total score in practice

Once points are summed, the simplified framework classifies:

• Probable AIH when the total is at least 6, reflecting a pattern that matched the original simplified instrument’s higher-sensitivity operating point for AIH likelihood in validation-style analyses.
• Definite AIH when the total is at least 7, reflecting a stricter operating point with greater specificity in many reported cohorts at the cost of missing some patients who still have treatable AIH by expert review.

Important nuances appear in real-world replication. External studies have emphasized excellent specificity for ruling in AIH at higher totals but variable sensitivity for the “definite” label; some patients with genuine AIH have biochemically mild IgG elevations or serologic understatement and therefore land in lower score bands. Conversely, overlap syndromes and cholestatic autoimmune diseases can occasionally generate point patterns that resemble AIH even when the final integrated diagnosis differs, which is why guideline-based diagnosis remains multidisciplinary.

Limitations and boundaries of the numeric tool

The simplified score does not incorporate items that the older revised IAIHG system could reward or penalize, such as female sex, alcohol intake thresholds, drug-exposure history detail, human leukocyte antigen associations, or graded responses to corticosteroids. Those omissions improve parsimony but mean that clinical judgment must fill the gaps. Low scores should not reflexively discard AIH when pretest probability, histologic sampling, or serologic methodology is suspect; high scores should not bypass thoughtful exclusion of drug-induced liver injury, metabolic disease, or vascular disorders when features argue against AIH.

Pediatric presentations often involve lower serologic titers that remain meaningful in the young; adult-oriented titre anchors may misclassify children if applied naively. Similarly, patients already treated with glucocorticoids or other immunomodulators may have partial serologic or biochemical normalization that depresses domain points even when the underlying diagnosis is AIH.

How this calculator supports (but does not replace) clinical care

The accompanying calculator is designed to reproduce the published domain logic transparently: you classify autoantibody tier, IgG relative ULN band, histology compatibility, and whether viral hepatitis has been appropriately excluded, then review the computed sum and category label. The output is intended for education, documentation prompts, and teaching rounds. Final diagnosis and treatment decisions must integrate individual risks, comorbidities, pregnancy or transplant considerations, patient preferences, and centre-specific pathways.

When scores fall near category boundaries, the most productive next steps are often repeat or complementary serology with methodologically consistent testing, expert liver pathology review, structured viral and metabolic evaluation, medication reconciliation with temporal correlation to liver test changes, and discussion with hepatology when immunosuppression is contemplated.